From the Journals

CARPREG II fine-tunes assessment of cardiac complication risk in pregnancy

View on the News

Detailed patient evaluation still required

This update and expansion of the original CARPREG scoring system is a “useful starting point” for prediction of the risk of pregnancy in women with cardiac disease, according to Uri Elkayam, MD.

However, a detailed and lesion specific evaluation is still required for a more precise determination of risk for any given patient, Dr. Elkayam cautioned in an editorial accompanying the article.

Clinicians need to thoroughly understand how the patient’s cardiac condition could be affected by hemodynamic changes during pregnancy, labor, delivery, and the postpartum period, Dr. Elkayam added in his comments.

To fully take advantage of CARPREG II, clinicians need to take into account the limitations of the scoring system, he said, including the fact that it is based on population studies.

“Although the system presented is designed to examine all adverse cardiac events that could have an impact on maternal health, it is less effective for distinguishing between mild and easily manageable events that do not have serious effects on maternal or fetal outcomes and those that may be severe, life-threatening, or require hospitalizations or early delivery,” he wrote.

Dr. Elkayam is with the department of medicine, division of cardiovascular medicine, and the department of obstetrics and gynecology, University of Southern California, Los Angeles. These comments are derived from his editorial in the Journal of the American College of Cardiology . Dr. Elkayam reported he had no relationships relevant to the contents of this paper to disclose.


 

FROM THE JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A study of pregnant women with heart disease has yielded a new risk index that improves on its predecessor by integrating general, lesion-specific, and delivery-of-care variables, investigators say.

“Compared with other published risk indices, including the original CARPREG [Cardiac Disease in Pregnancy] score, CARPREG II risk index had the highest discriminative and calibrative accuracy in our study group,” investigators said in a report published in the Journal of the American College of Cardiology.

First author on the report was Candice K. Silversides, MD, division of cardiology, University of Toronto pregnancy and heart disease research program, Mount Sinai Hospital/Sinai Health System.

The widely used, original CARPREG risk index was the first to predict maternal cardiac complications based on general clinical and echocardiographic data from the baseline antepartum visit, the researchers wrote in their report.

The new index developed by Dr. Silversides and her colleagues stems from a study of pregnant women with heart disease receiving care at two large Canadian obstetric centers.

Based on analysis of 1,938 pregnancies progressing beyond 20 weeks of gestation, the investigators found that cardiac complications were overall quite common in pregnant women with heart disease, occurring in 16% of participants. However, maternal cardiac deaths or cardiac arrests were rare, they said, occurring in just 11 (0.6%) of the pregnancies.

Most complications (64%) occurred in the antepartum period, according to the report.

Pages

Recommended Reading

EAGLES: Smoking cessation therapy did not up cardiovascular risk
MDedge Family Medicine
Life and health are not even across the U.S.
MDedge Family Medicine
MDedge Daily News: Can a nasal spray reverse suicidality?
MDedge Family Medicine
FDA advisory committee votes to recommend update to celecoxib safety labeling
MDedge Family Medicine
MDedge Daily News: Lupus is quietly killing young women
MDedge Family Medicine
MI before age 50? Think familial hypercholesterolemia, substance abuse
MDedge Family Medicine
Women’s representation in CV drug trials still lagging
MDedge Family Medicine
Stroke-smoking link is dose dependent in young men
MDedge Family Medicine
Does warfarin cause acute kidney injury?
MDedge Family Medicine
First reversal agent for apixaban and rivaroxaban gets fast-track approval
MDedge Family Medicine